Aptose Biosciences (APTO)
NASDAQ:APTO

Aptose Biosciences (APTO) Income Statement

1,075 Followers

Aptose Biosciences Income Statement

Last quarter (Q4 2022), Aptose Biosciences's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Aptose Biosciences's net income was $-10.00M. See Aptose Biosciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
--$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 42.60M$ 42.60M$ 65.45M$ 55.77M$ 26.86M$ 29.11M
Operating Income
$ -42.60M$ -42.60M$ -65.45M$ -55.77M$ -26.86M$ -29.11M
Net Non Operating Interest Income Expense
$ 788.00K$ 788.00K$ 94.00K$ 522.00K$ 574.00K$ 283.00K
Other Income Expense
$ -11.00K-$ -1.00K$ 8.00K$ 6.00K$ -44.00K
Pretax Income
$ -41.82M$ -41.82M$ -65.35M$ -55.24M$ -26.28M$ -28.87M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -41.82M$ -41.82M$ -65.35M$ -55.24M$ -26.28M$ -28.87M
Basic EPS
$ -0.45$ -0.45$ -0.73$ -0.67$ -0.52$ -0.86
Diluted EPS
$ -0.45$ -0.45$ -0.73$ -0.67$ -0.52$ -0.86
Basic Average Shares
$ 276.85M$ 92.27K$ 89.09M$ 81.84M$ 50.16M$ 33.39M
Diluted Average Shares
$ 276.85M$ 92.27K$ 89.09M$ 81.84M$ 50.16M$ 33.39M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 42.60M$ 42.60M$ 65.45M$ 55.77M$ 26.86M$ 29.11M
Net Income From Continuing And Discontinued Operation
$ -41.82M$ -41.82M$ -65.35M$ -55.24M$ -26.28M$ -28.87M
Normalized Income
$ -41.81M$ -41.82M$ -65.35M$ -55.25M$ -26.28M$ -28.82M
Interest Expense
------
EBIT
$ -42.60M$ -42.61M$ -65.45M$ -55.77M$ -26.86M$ -29.11M
EBITDA
$ -31.77M-$ -64.83M$ -55.15M$ -26.24M$ -29.02M
Currency in USD

Aptose Biosciences Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis